UK weight-loss medicines compared
Interest in prescription weight-management medicines has grown sharply. Supply, commissioning, and eligibility vary, so patients often ask how Mounjaro, Wegovy (injectable semaglutide), Wegovy Pill (oral semaglutide where licensed), Nevolat (liraglutide), and Mysimba differ—and what is appropriate only under clinical supervision.
Several active ingredients have MHRA-approved presentations for obesity and/or related conditions. Many injectable options now discussed in UK practice are once-weekly GLP-1–based therapies (injectable semaglutide or tirzepatide), while daily liraglutide remains relevant for some patients. Oral semaglutide for weight management is an additional presentation in some markets; it is not interchangeable with the weekly injection. Oral therapies such as Mysimba follow different rules for eligibility and monitoring.
This overview summarises mechanisms, typical dosing patterns, and themes from trials—it is not a substitute for personalised medical advice. For a focused two-way injectable comparison, see Mounjaro vs Wegovy. For injectable vs oral semaglutide, see Wegovy injection vs Wegovy Pill. For investigational retatrutide (triple agonist), see Retatrutide vs Mounjaro: triple-action worth the wait? For UK treatment options and pricing context after a clinician approves a plan, see weight loss treatments and our weight loss service hub.